Novartis Kymriah trial: strong response rates, safety profile in relapsed or refractory follicular lymphoma

  -- Primary analysis of ELARA trial demonstrated a 66% complete response rate

      and 86% overall response rate with one-time Kymriah infusion1 
 
   -- Robust response observed in heavily pretreated patients in critical need 
      of a potentially definitive treatment option1,2 
 
   -- No patients in ELARA trial experienced grade 3/4 cytokine release 
      syndrome, the most common side effect associated with CAR-T therapy1 
 
   -- Global regulatory submissions based on the ELARA trial on track for later 
      this year

https://www.marketscreener.com/quote/stock/NOVARTIS-AG-9364983/news/Press-Release-nbsp-Novartis-Kymriah-R-pivotal-trial-demonstrates-strong-response-rates-and-a-rema-35500399/